- Country: Argentina
- Summary: Medicines-Pregabalina and Other-Various-Phymacy Pas
- ART Ref No: 117817918
- Deadline: 25 Apr 2025
- Financier: Self Financed
- Purchaser Ownership: Government
- Tender Value: ARS 5255905.20
- Notice Type: Tender
- Document Ref. No.: 430-0604-CDI25
- Purchaser's Detail:Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
- Description:
- Pracebalin. Model: 25 mg, in tablet, Piribedil Retard. Model: 50 mg in tablet, lacosamide. Model: 100 mg, in covered tablet, lacosamide. Model: 50 mg, in tablet, mesalazine. Model: 800 mg, in tablet, other specifications will be indicated will be indicatedfor the requesting distribution. Model: 40 mg., In tablets., Betahistine dichlorhydrate. Model: 16 mg, in tablet, sodium Hialuronato Model: 0.2 g, solution, in flag x 10 ml, amitriptyline model: 25 mg (as hydrochloride), in covered tablet, diclofenac sodic + pridinolMesilato Model: 50 mg of diclofenac sodium + 4 mg of mesilate priidinol, in tablet.
- Documents:
If you are registered member, kindly login to view full details of this tender notice:
CLICK HERE TO LOGINMedicines-Pregabalina and Other-Various-Phymacy Pas - Argentina Tender
The HTAL. JOSE M. WE MEJIA, a Government sector organization in Argentina, has announced a new tender for Medicines-Pregabalina and Other-Various-Phymacy Pas. This tender is published on ArgentinaTenders under ART Ref No: 117817918 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2025-04-25.
The estimated tender value is ARS 5255905.20, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.
